F18 RADIOPHARMACEUTICALS
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), specifically the Atlanta Veterans Affairs Healthcare System (ATL VA HCS), is soliciting proposals for the supply of F18 Radiopharmaceuticals and related services. This Solicitation aims to secure a vendor for daily delivery of various F18-labeled radiopharmaceuticals to the Nuclear Medicine Service in Decatur, GA. This acquisition is a Total Small Business Set-Aside. Offers are due by April 30, 2026, at 10:00 AM EST.
Scope of Work
The selected vendor will provide all labor, supervision, and transportation for the daily delivery of F18-FDG, F18-NaF, F18-beta-amyloid imaging agents, F18-Axumin, F18-Tauvid, F18-Cerianna, F18-Posluma, F18-Pylarify, CAIX targeted PET radiopharmaceutical, choline PET radiopharmaceuticals, and F18-FET. Deliveries are required daily to the NM Service hot lab (Rm 1C335) during standard business hours (Monday-Friday, 07:00-17:00), with provisions for emergency deliveries. Key requirements include specific labeling for unit doses, multi-dose vials, and syringes, performance of all necessary quality control, and outlining contingency protocols for F18 shortages. Full compliance with US and GA regulations for radioactive materials is mandatory.
Contract & Timeline
- Contract Type: Firm-Fixed-Price
- Period of Performance: One-year base period (March 20, 2026 - March 19, 2027) with four (4) one-year option periods.
- Set-Aside: Total Small Business Set-Aside
- NAICS Code: 325412 (Pharmaceutical and Medicine Manufacturing)
- Size Standard: 1300 Employees
- Offer Due Date: April 30, 2026, at 10:00 AM EST
- Published Date: April 10, 2026
Evaluation
Proposals will be evaluated based on Technical factors and Past Performance, which will be considered more significant than price. Technical evaluation includes proposal outline, small business status, SAM exclusions, financial stability, Letters of Supply (LOS) document, licenses, and FDA approval for cyclotrons.
Additional Notes
Vendors must be licensed by the US NRC and/or an Agreement State, and cyclotrons used must be FDA approved. Attachments include a table of Products, Doses, and Estimated Volumes (Attachment 1) and a Quality Assurance Surveillance Plan (QASP) (Attachment 2). No access to VA sensitive information or a Security Accreditation Package is required.